My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 321

    1.

    Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.

    Meyer C, McGrath BP, Teede HJ.

    Diabetes Care. 2007 Mar;30(3):471-8.PMID: 17327307 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.

    Hutchison SK, Harrison C, Stepto N, Meyer C, Teede HJ.

    Diabetes Care. 2008 Jul;31(7):1427-32. Epub 2008 Apr 4.PMID: 18390799 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.

    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.

    J Clin Endocrinol Metab. 2000 Sep;85(9):3161-8.PMID: 10999803 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.

    Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS.

    J Clin Endocrinol Metab. 2003 Jan;88(1):148-56.PMID: 12519844 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.

    Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M, Elsenbruch S, Kimmig R, Mann K, Janssen OE.

    Eur J Endocrinol. 2007 Nov;157(5):669-76.PMID: 17984248 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.

    Yilmaz M, Biri A, Karakoç A, Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M.

    J Endocrinol Invest. 2005 Dec;28(11):1003-8.PMID: 16483179 [PubMed - indexed for MEDLINE]Related articles

    7.

    Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.

    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF.

    J Clin Endocrinol Metab. 2007 Jul;92(7):2453-61. Epub 2007 Apr 10.PMID: 17426085 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.

    Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randeva H, Schernthaner G, Lehnert H.

    J Clin Endocrinol Metab. 2008 Jan;93(1):82-90. Epub 2007 Nov 6.PMID: 17986642 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.

    Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ.

    Fertil Steril. 2008 Nov 17. [Epub ahead of print]PMID: 19019358 [PubMed - as supplied by publisher]Related articles

    10.

    Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.

    Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N.

    Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005552. Review.PMID: 17253562 [PubMed - indexed for MEDLINE]Related articles

    11.

    Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.

    Arslanian SA, Lewy V, Danadian K, Saad R.

    J Clin Endocrinol Metab. 2002 Apr;87(4):1555-9.PMID: 11932281 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study.

    Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R, Colao A.

    J Clin Endocrinol Metab. 2005 Nov;90(11):6072-6. Epub 2005 Aug 23.PMID: 16118336 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.

    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.

    Hum Reprod. 2006 Jan;21(1):121-8. Epub 2005 Sep 30.PMID: 16199428 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.

    Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R.

    J Clin Endocrinol Metab. 2008 Jul;93(7):2670-8. Epub 2008 May 6.PMID: 18460557 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome.

    Allen HF, Mazzoni C, Heptulla RA, Murray MA, Miller N, Koenigs L, Reiter EO.

    J Pediatr Endocrinol Metab. 2005 Aug;18(8):761-8.PMID: 16200842 [PubMed - indexed for MEDLINE]Related articles

    16.

    Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.

    Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A.

    J Endocrinol. 2005 Jan;184(1):233-9.PMID: 15642799 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.

    Glueck CJ, Goldenberg N, Sieve L, Wang P.

    Metabolism. 2008 Jul;57(7):954-60.PMID: 18555837 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.

    Wu J, Zhu Y, Jiang Y, Cao Y.

    Gynecol Endocrinol. 2008 Jul;24(7):392-8.PMID: 18608522 [PubMed - indexed for MEDLINE]Related articles

    19.

    Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome.

    Palomba S, Falbo A, Russo T, Manguso F, Tolino A, Zullo F, De Feo P, Orio F Jr.

    J Clin Endocrinol Metab. 2007 Aug;92(8):3128-35. Epub 2007 May 22.PMID: 17519312 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.

    Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE.

    J Clin Endocrinol Metab. 2004 Jan;89(1):242-9.PMID: 14715857 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity